Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Genprex, Inc.
  6. News
  7. Summary
    GNPX   US3724461047

GENPREX, INC.

(GNPX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genprex Shares Rise 8% on FDA Review of Reqorsa Trial

06/23/2021 | 08:57am EDT

By Chris Wack

Genprex Inc. shares were up 8% to $3.57 after the company said the U.S. Food and Drug Administration has reviewed and confirmed all comments have been addressed regarding the clinical trial protocol for the Phase 1/2 clinical trial evaluating Reqorsa Immunogene Therapy.

The company said the trial was done in combination with AstraZeneca PLC's Tagrisso in patients with late-stage non-small cell lung cancer whose disease progressed after treatment with Tagrisso.

In January 2020, Genprex received FDA Fast Track Designation for the trial's patient population.

Genprex has engaged its first clinical site for the trial, and is continuing to work with a number of other cancer research centers and academic institutions to select optimal study sites.

The company expects the Phase 1 portion of the trial to enroll up to 18 patients at three clinical sites and for the Phase 2 portion to enroll 74 patients at up to 15 clinical sites. The first part of the Phase 1/2 clinical trial will be a dose escalation study.

The primary endpoint of the Phase 2 portion of the trial is progression-free survival, which is defined as time from randomization after first progression on Tagrisso, to first event or death. An interim analysis will be performed at 51 events.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-23-21 1057ET

All news about GENPREX, INC.
07/20GENPREX : to Participate in a Monthly CEO Roadshow Webinar Series
BU
07/12GENPREX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/28GENPREX : Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQ..
PU
06/28GENPREX, INC. : Submission of Matters to a Vote of Security Holders, Other Event..
AQ
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 3000E Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 2000 Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell Small Cap Completeness Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 3000 Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 3000E Growth Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 2500 Growth Index
CI
More news
Financials (USD)
Sales 2021 15,0 M - -
Net income 2021 -23,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -37,1x
Yield 2021 -
Capitalization 141 M 141 M -
Capi. / Sales 2021 9,38x
Capi. / Sales 2022 5,63x
Nbr of Employees 12
Free-Float 89,4%
Chart GENPREX, INC.
Duration : Period :
Genprex, Inc. Technical Analysis Chart | GNPX | US3724461047 | MarketScreener
Technical analysis trends GENPREX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,97 $
Average target price 8,25 $
Spread / Average Target 178%
EPS Revisions
Managers and Directors
J. Rodney Varner Executive Chairman, President, CEO & Secretary
Ryan M. Confer Chief Financial Officer
Shannon Inman Vice President-Global Clinical Operations
Michael T. Redman Chief Operating Officer & Executive Vice President
Brent M. Longnecker Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENPREX, INC.-28.43%141
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE317.33%79 303
WUXI APPTEC CO., LTD.36.10%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-16.09%52 296